Aflibercept may reduce risk of proliferative diabetic retino
Investigators evaluated the efficacy of intravitreous aflibercept injections in mitigating complications in eyes with moderate to severe nonproliferative diabetic retinopathy (NPDR).

The DRCR Retina Network Protocol W included adults with type 1 or 2 diabetes and moderate to severe nonproliferative diabetic retinopathy. Researchers randomized 399 eyes to receive 2 mg of intravitreal aflibercept or sham injections at baseline and at each study visit through 2 years (1, 2, and 4 months, and then every 4 months). The primary outcome was the development of center-involved diabetic macular edema (DME) with vision loss or proliferative diabetic retinopathy (PDR).

Compared with the sham group, the aflibercept group had a lower 2-year cumulative probability of developing proliferative diabetic retinopathy (14.5% vs. 33.2%) and diabetic macular edema (4.1% vs. 14.8%). The cumulative probability of developing high-risk proliferative diabetic retinopathy any time within 2 years was 2.4% with aflibercept and 8.9% with sham. During the study period, the average change in visual acuity was -0.9 letters with aflibercept and -2 letters with sham.

Among eyes with moderate to severe nonproliferative diabetic retinopathy, aflibercept conferred a more than 3-fold reduction in the incidence of center-involved diabetic macular edema and a more than 2-fold reduction in proliferative diabetic retinopathy. However, through 2 years, preventive treatment did not provide improved visual acuity compared with observation plus aflibercept if complications developed.

Source:https://www.aao.org/editors-choice/aflibercept-may-reduce-risk-of-pdr-dme-in-patients
Like
Comment
Share